VIBRANT Study of Vurolenatide in Adult Patients With Short Bowel Syndrome.
A Phase 2, Double-Blind, Double-Dummy, Placebo-Controlled, Multicenter Study of the Efficacy, Safety, and Tolerability of Vurolenatide in Adult Patients With Short Bowel Syndrome
Sponsor: 9 Meters Biopharma, Inc.
Terminated
Trial terminated by Sponsor
Other terminated trials from 9 Meters Biopharma, Inc.
More terminations from 9 Meters Biopharma, Inc.
Other Short Bowel Syndrome trials with similar outcome
This PHASE2 trial investigates Short Bowel Syndrome and is currently terminated or withdrawn. 9 Meters Biopharma, Inc. leads this study, which shows 4 recorded versions since 2021 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
4 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Jan 2023 — Jul 2024 [monthly]
Terminated PHASE2
Status: Recruiting → Terminated
-
Sep 2021 — Jan 2023 [monthly]
Recruiting PHASE2
First recorded
Jun 2021
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- 9 Meters Biopharma, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .